MONHEIM, Germany, January 13, 2025 / Biotech Newswire / -- Cube Biotech and IBA Lifesciences, two leading innovators in the biotechnology industry, join forces to create a unified powerhouse dedicated to advancing research and production capabilities for the life science industry. The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets.
Cube Biotech's vision to accelerate innovation, simplify services, and broaden its global presence is reflected in the acquisition. Over the course of the last 12 months, the company has formed multiple collaborations to realize these goals. By combining Cube Biotech’s expertise in protein technologies with IBA Lifesciences strength in high performance research tools for protein isolation and analysis, the new entity is uniquely positioned to address the evolving needs of researchers and industry professionals worldwide.
Strategic Highlights of the Acquisition:
- Enhanced Product Portfolio: Integration of Cube Biotech’s portfolio of stabilized membrane proteins via its NativeMP™ platform and purification resins with IBA Lifesciences’ proprietary Strep-tag® affinity technology.
- Global Reach: Expanding distribution channels and operational capabilities to better serve customers in North America, Europe, and Asia.
- Innovative R&D Synergy: Combining research and development teams to drive groundbreaking advancements in life science research and the drug discovery value chain.
- Customer-Centric Solutions: Focus on delivering comprehensive, customizable solutions tailored to the specific needs of pharmaceutical, biotech and academic customers.
Didier Dargent, CEO of Cube Biotech, stated, “This acquisition marks an exciting new chapter for both companies. Together, we will harness our collective expertise to push the boundaries of what’s possible in the life sciences and enable researchers to make groundbreaking discoveries.”
Mike Rothe, CEO of IBA Lifesciences, added, “The fusion of our technologies and talents creates an outstanding foundation for innovation. Our combined efforts will benefit our customers and strengthen our position as leaders in the biotechnology market.”
About Cube Biotech GmbH
Headquartered in Monheim, Germany, Cube Biotech is a leading provider of solutions for protein purification, stabilization, and structural studies. Known for its high-quality purification resins and membrane protein stabilization kits, Cube Biotech serves researchers across academia and industry. Cube Biotech is an ARCHIMED company since 2021.
About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.
About IBA Lifesciences GmbH
Based in Göttingen, Germany, IBA Lifesciences is renowned for its pioneering Strep-tag® system and innovative solutions in protein applications. With a strong focus on high-quality tools for biomolecular research, IBA Lifesciences has earned a global reputation for excellence.
For more information about the acquisition or to speak with a representative, please contact:
Contact
Cube Biotech
Michael Ries
Head of Sales and Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Drug Discovery; Proteins; Biological Science Disciplines; Cube Biotech; IBA Lifesciences; Membrane protein production; Purification technologies; Acquisition; Monheim, Germany; Göttingen, Germany; Biotechnology industry; Protein purification; Protein stabilization; Life science industry; Protein technologies; Research tools; Protein isolation; Protein analysis; NativeMP platform; Strep-tag® affinity technology; Research and development; Drug discovery value chain; Didier Dargent; Michael Ries; Mike Rothe; Strep-tag® system
Source: Biotech Newswire